We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Stability of Cardiac Biomarkers Tested in Different Samples

By LabMedica International staff writers
Posted on 09 Jan 2018
Print article
Image: The ARCHITECT i2000SR immunoassay analyzer (Photo courtesy of Abbott Diagnostics).
Image: The ARCHITECT i2000SR immunoassay analyzer (Photo courtesy of Abbott Diagnostics).
Blood-based biomarkers, such as cardiac troponin (cTn) and galectin-3, are widely used in clinical trials and/or in clinical routines as an aid for the diagnosis and risk stratification of patients with heart disease.

When blood samples are used for biomarker measurements in clinical routine analyses, efforts should be made to process these samples immediately after blood collection to provide immediate results for timely diagnosis and therapy and to avoid any pre-analytical errors.

Doctors at Konventhospital Barmherzige Brueder Linz, (Linz, Austria) tested the hypothesis that the analytes hs-cTnI, hs-cTnT and galectin-3 are stable in vitro at a storage temperature of −80 °C for at least one year, and they used blood samples from clinical routine analyses. The analyte concentrations of 30 patients were measured in heparin-treated plasma, EDTA-treated plasma and serum samples after the following storage conditions: 1) samples used immediately after blood collection for baseline measurements; 2) samples stored for six months at −80 °C after one freeze-thaw cycle; 3) samples stored for one year at −80 °C after two freeze-thaw cycles; and 4) samples stored for one year at −80 °C after one freeze-thaw cycle.

Circulating concentrations of high-sensitivity cardiac troponin I (hs-cTnI) were measured with the STAT High Sensitive Troponin-I assay on the Abbott ARCHITECT i2000SR analyzer. The team measured hs-cTnT concentrations with the Troponin T hs assay on the Roche cobas e 411. The scientists also measured galectin-3 with the Abbott Diagnostics routine Galectin-3 assay on an ARCHITECT i2000SR analyzer.

The investigators reported that baseline hs-cTnI, hs-cTnT and galectin-3 concentrations ranged from 2.3 to 5,436 ng/L, from 5.3 to 850 ng/L, and from 8.3 to 79.3 ng/mL, respectively. After applying the default criterion for analyte stability, the three analytes were stable for at least one year even after two freeze-thaw cycles for each sample type. They observed the following variation in analyte concentrations after storage relative to the baseline values: the interquartile range (IQR) of cardiac troponin results extended from approx. 80% to 115%, and the IQR of galectin-3 results extended from approx. 90% to 110%.

The authors concluded that hs-cTnI, hs-cTnT and galectin-3 were stable under the reported storage conditions irrespective of the sample type used. However, they observed a considerable variation in analyte concentrations after sample storage, which might affect the diagnostic/prognostic value of these analytes in individual patients using frozen blood samples. The study was published in the January 2018 issue of the journal Clinica Chimica Acta.

Related Links:
Konventhospital Barmherzige Brueder

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: Fingertip blood sample collection on the Babson Handwarmer (Photo courtesy of Babson Diagnostics)

Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection

Warming the hand is an effective way to facilitate blood collection from a fingertip, yet off-the-shelf solutions often do not fulfill laboratory requirements. Now, a unique hand-warming technology has... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.